Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$49.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

UCB announces data from extension clinical trial of Cimzia


Monday, 5 May 2014 09:07am EDT 

UCB SA:Announces results from PRECiSE 3 seven-year open label extension clinical trial of Cimzia (certolizumab pegol), evaluating long-term safety in Crohn's disease.Remission also assessed over trial period.595 patients enrolled in PRECiSE 3 following completion of PRECiSE 1 and 2 pivotal studies (354 enrolled from PRECiSE 1 and 241 enrolled from PRECiSE 2).No new safety signals identified during study.Patients treated with Cimzia are at increased risk for developing serious infections that may lead to hospitalization or death. 

Company Quote

69.31
-0.4 -0.57%
5:31am EDT